bioRxivCancer BiologyPreprint
Mutant p53 Misfolding and Aggregation Precedes Transformation into High-Grade Serous Ovarian Carcinoma
Sara SartiniiD, Lexi Omholt, Neda A. MoatamediD, Alice SoragniiD
Abstract
High Grade Serous Ovarian Cancer (HG-SOC), the most prevalent and aggressive gynecological malignancy, is marked by ubiquitous loss of functional p53, largely due to point mutations that arise very early in carcinogenesis. These mutations often lead to p53 protein misfolding and subsequent aggregation, yet the alterations in intracellular p53 dynamics throughout ovarian cancer progression remain poorly understood. HG-SOC originates from the fallopian tube epithelium, with a well-documented stepwise progression beginning with early pre-malignant p53 signatures. These signatures represent largely normal cells that express and accumulate mutant p53, which then transform into benign serous tubal intraepithelial lesions (STIL), progress into late pre-malignant serous tubal intraepithelial carcinoma (STIC), and ultimately lead to HGSOC. Here, we show that the transition from folded, soluble to aggregated mutant p53 occurs during the malignant transformation of benign precursor lesions into HGSOC. We analyzed fallopian tube tissue collected from ten salpingo-oophorectomy cases and determined the proportion of cells carrying soluble versus mis-folded/mutant p53 through conformation-sensitive staining and quantification. Misfolded p53 protein, prone to aggregation, is present in STICs and HG-SOCs, but notably absent from preneoplastic lesions and surrounding healthy tissue. Overall, our results indicate that aggregation of mutant p53 is a structural defect that distinguishes preneoplastic early lesions from late premalignant and malignant ones, offering a potential treatment window for targeting p53 aggregation and halting ovarian cancer progression.
- organism: human
- assay: protein structure
- research focus: cell type annotation
- approach: experimental assay
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The genomic trajectory of ovarian high grade serous carcinoma is determined in STIC lesions
Z. Cheng, D. P. Ennis, … I. A. McNeish·bioRxiv·Mar 11, 2024
- Most commonly mutated genes in High Grade Serous Ovarian Carcinoma are nonessential for ovarian surface epithelial stem cell transformation
R. J. Yamulla, S. Nalubola, … J. C. Schimenti·bioRxiv·Jan 27, 2020
- TP53 loss initiates chromosomal instability in high-grade serous ovarian cancer
D. Bronder, D. Wangsa, … S. S. Taylor·bioRxiv·Mar 12, 2021
- Stromal mediated DNA damage promotes high grade serous ovarian cancer initiation
Geyon L. Garcia, Taylor J. Orellana, … Lan Gardner Coffman·Cancer DiscoveryPeer-reviewed·Mar 14, 2025
- The genomic landscape of early stage ovarian high grade serous carcinoma
Z. Cheng, H. Mirza, … I. McNeish·bioRxiv·May 5, 2021
- MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model
A. Blackman, A. C. Rees, … J. R. Delaney·bioRxiv·Jan 24, 2024